Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

BIZARRE: Pacira biosciences s return on invested capital overview - What They Never Told You

Pulled from Benzinga Pro data, Pacira BioSciences (NASDAQ:PCRX) posted Q1 earnings of $6.83 million, an increase from Q4 of 233.1%. Sales dropped to $157.99 million, a 0.76% decrease between quarters. In Q4, Pacira BioSciences brought in $159.19 million in sales but lost $5.13 million in earnings.

What Is Return On Invested Capital?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.